INTSIntensity Therapeutics Inc. Common stock
4.860USD+15.71%Mkt Cap: 15.87M $P/E: —3d ago
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead produc…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap15.87M $
Enterprise Value6.50M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.61M $
Revenue/Share—
Last Price4.860 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.45
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.24
EPS (TTM)-2.27
EPS (Forward)-1.99
52W Range
3.5103% of range43.50
52W High43.50 USD
52W Low3.510 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-97.73%
ROA-82.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.23M $
CapEx (TTM)—
FCF Margin—
FCF Yield-39.59%
Net Debt-9.43M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio5.00
Quick Ratio4.25
Book Value/Sh3.928 USD
Cash/Share2.919 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateFeb 19, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)19.33 USD
Upside (mean)+297.8%
Target Range7.000 USD – 32.00 USD
$7.000+297.8% to mean$32.00
# Analysts6
Ownership
Shares Out.3.26M
Float3.04M
Insiders3.77%
Institutions21.36%
Short Interest
Short Ratio1.5d
Short % Float2.65%
Short % Out.2.53%
Shares Short68.36K
Short (prev mo.)126.42K
Technical
SMA 504.285 (+13.4%)
SMA 2007.024 (-30.8%)
Beta3.03
S&P 52W Chg18.16%
Avg Vol (30d)26.42K
Avg Vol (10d)28.49K
Technical Indicators
RSI (14)65.2
MACD-0.0231
MACD Signal-0.0608
MACD Hist.+0.0377
BB Upper4.699 USD
BB Middle4.270 USD
BB Lower3.842 USD
BB Width20.07%
ATR (14)0.2787 USD
Vol Ratio (20d)0.77x